Solid outlook from Valeant, promised changes, fire up shares

Drugmaker Valeant Pharmaceuticals, a fast-growing Wall Street darling until its price-hiking business strategy made it a symbol of pharmaceutical company greed, said it's undergoing a restructuring as its new CEO attempts to turn it around and repair its tattered reputation.